CSBio CSBio

X
[{"orgOrder":0,"company":"Veralox Therapeutics","sponsor":"Hatteras Venture","pharmaFlowCategory":"D","amount":"$16.6 million","upfrontCash":"Undisclosed","newsHeadline":"Veralox Therapeutics Announces Closing Of $16.6 Million Series A Financing And Announces New Board Members","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Veralox Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            The Series A financing, will support Veralox's efforts to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).

            Lead Product(s): VLX-1005

            Therapeutic Area: Hematology Product Name: VLX-1005

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Hatteras Venture

            Deal Size: $16.6 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing June 16, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY